- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02444611
A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study (ELVIS)
A Randomised, Controlled Trial Investigating the Influence of BCG (Bacillus Calmette-Guérin) and Hepatitis B Immunisation at Birth on Neonatal Immune Responses
Neonatal morbidity and mortality from infectious diseases is of global concern. Childhood disease-specific immunisation is irrefutably linked to the decline in deaths from these targeted infections over the last century. However, neonatal immunisation is limited, in part, by the impaired adaptive immune function in this age group.
There is now an expanding body of evidence for heterologous ('non-specific') effects of various vaccines used in childhood. This refers to the immunomodulatory capabilities of vaccines to influence immune outcomes beyond the vaccine's specific targeted disease. The underlying immunological mechanisms responsible for these effects are incompletely understood, but evidence is mounting that the innate immune system is central to these observed effects.
This study is a randomised controlled trial designed to determine the influence of two commonly administered neonatal immunisations, BCG and Hepatitis B vaccine, given at birth, on the neonatal immune responses to non-specific antigens.
The investigators will recruit 200 newborns at the Mercy Hospital for Women in Melbourne, Australia over a 1-year period. These babies will be allocated randomly to one of 4 groups, receiving these 2 vaccines in different combinations, at 2 set time points. (at birth and 1 week post randomisation) A blood sample will be taken at 1-week post randomisation for in vitro immunological analyses.
This study will improve current understanding of the influence of vaccines on neonatal immunity and will help develop strategies exploiting beneficial heterologous ('non-specific') effects to improve protection against infection in the very young.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Mercy Hospital for Women
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- English speaking parent
- Planned travel to a TB (Tuberculosis) endemic country within the infant's first 5 years of life
- An informed consent form must be signed and dated by the infant's mother after the nature of the study has been explained and prior to any study assessments/procedures
- The infant's mother has screened negative for HIV during this pregnancy
- The infant's mother has screened negative for Hepatitis B during this pregnancy
- There is no known household contact infected with Hepatitis B
- Born no earlier than eight weeks before estimated date of delivery
- Birth weight >1500g
- Delivered vaginally
- Singleton pregnancy
Exclusion Criteria:
- Known or suspected HIV infection
- Treatment with corticosteroids or other immunosuppressive therapy, including monoclonal antibodies against tumour necrosis factor---alpha (TNF---alpha) (e.g. infliximab, etanercept, adalimumab).
- Born to a mother treated with bDMARDs (biological Disease- Modifying Anti-Rheumatic drugs) (e.g. TNF---alpha blocking monoclonal antibodies) in the 3rd trimester
- Congenital cellular immunodeficiencies including specific deficiencies of the interferon gamma pathway
- Malignancies involving bone marrow or lymphoid systems
- Serious underlying illness including severe malnutrition
- Medically unstable
- Generalised septic skin disease and skin conditions such as eczema, dermatitis and psoriasis
- Significant febrile illness
Also excluded are infants with:
- A mother who is immunosuppressed;
- A mother who has received Intravenous immunoglobulins during her pregnancy
- A family history of immunodeficiency;
- Consanguineous parents.
- Mother who is having a planned Caesarean Section
- A home address more than 40 minutes drive from the Mercy hospital for Women and are unwilling to return to hospital for infant blood sampling
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group 1
BCG vaccine, 0,05ml intradermally at birth
|
intradermal vaccination
Other Names:
|
Active Comparator: Group 2
BCG vaccine, 0,05ml intradermally at birth Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
|
intradermal vaccination
Other Names:
intramuscular vaccination
Other Names:
|
Active Comparator: Group 3
Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
|
intramuscular vaccination
Other Names:
|
No Intervention: Group 4
No birth vaccines
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cytokine concentrations (pg/ml) in response to in-vitro stimulation with a range of antigens
Time Frame: 7 (+-4) days post randomisation
|
Four hours after blood samples are collected, they will be stimulated with different concentrations of infective antigens for 20hrs. (eg killed S.aureus, S. pneumoniae, E. Coli, Haemophilus Influenza B, Group B streptococcus, C. albicans), BCG, Hepatitis B sAg). Cytokine expression will be analysed in supernatants by Luminex -based multiplex assays. The cytokines that will be measured: Interleukin-1 beta, Interleukin-1ra, Interleukin-6, Interleukin-8, Macrophage/Monocyte Chemoattractant Protein-1(MCP-1), Macrophage Inflammatory Protein (MIP) -1 alpha, MIP-1 beta, Interferon(IFN) gamma, Interleukin-10, Macrophage migration inhibitory factor (MIF), Monokine induced by interferon (MIG), Tumour necrosis factor (TNF) alpha |
7 (+-4) days post randomisation
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nigel Curtis, MBBS,PHD, Royal Children's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAC/01 ELVIS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Innate Immune Response
-
Radboud University Medical CenterCompletedInnate Immune Response
-
Society for Applied StudiesNorwegian Institute of Public Health; Christian Medical College, Vellore, IndiaCompletedInnate Immune ResponseIndia
-
Radboud University Medical CenterCompletedInnate Immune Response | Immune Tolerance
-
Radboud University Medical CenterCompletedInnate Immune ResponseNetherlands
-
Radboud University Medical CenterUMC Utrecht; Prothya BiosolutionsCompletedSepsis | Inflammation | Endotoxemia | Innate Immune ResponseNetherlands
-
University of ValladolidDanone Institute International; University of SevilleCompletedImmune System | Innate Inflammatory Response
-
Washington University School of MedicineActive, not recruitingPregnancy Related | Innate Inflammatory ResponseUnited States
-
Milton S. Hershey Medical CenterActive, not recruiting
-
University Hospital, ToulouseTerminatedInnate Immune ResponsesFrance
-
Cambridge University Hospitals NHS Foundation TrustRecruiting
Clinical Trials on BCG Vaccine
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Completed
-
Murdoch Childrens Research InstituteRoyal Children's Hospital; University of Melbourne; Mercy Hospital for Women,...Active, not recruitingRespiratory Tract Infections | Allergy | EczemaAustralia
-
Hellenic Institute for the Study of SepsisCompletedVirus Diseases | COVID-19 | Chronic Obstructive Pulmonary Disease | Coronary Heart Disease | Corona Virus InfectionGreece
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...Active, not recruitingHPV InfectionUnited States
-
Universidad de AntioquiaWithdrawn
-
Green Signal Biopharma Private LimitedCompleted
-
Assiut UniversityNot yet recruiting
-
Steven E Arnold, MDActive, not recruitingAlzheimer Disease | Mild Cognitive Impairment | Mild Dementia | Moderate DementiaUnited States
-
Radboud University Medical CenterCompleted
-
Johns Hopkins UniversityCystic Fibrosis FoundationCompletedCystic Fibrosis | Bronchiectasis Adult | Non-Tuberculous MycobacteriaUnited States